We would love to hear your thoughts about our site and services, please take our survey here.
Just been reading Avacta website again:
“Avacta took its first pre|CISIONTM drug candidate AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic in summer 2021. The Company anticipates the results of this phase 1 study which will demonstrate safety and mechanism of action late in 2022 which will pave the way for further clinical development of AVA6000 and other pre|CISIONTM targeted chemotherapies.”
An RNS will come this year IMO.
The same website page also states:
“Avacta’s Diagnostics division, based in Wetherby, UK., is using the Affimer® platform with the aim of developing market leading diagnostic products.
Alongside this organic growth strategy Avacta is delivering an ambitious M&A led growth strategy to consolidate in the fragmented European diagnostics sector with the aim of building a substantial in-vitro diagnostics business with global-reach and delivering significant value to shareholders.”
The M&A strategy was only mentioned recently in the last RNS. There’d been no mention of it before. Therefore, I say this is a recent update and the results of the Phase 1 study will come in the next 2 weeks !
I know the majority on here are children and for those of you Christmas starts on 1 December, but there’s 21/22 days left until the end of Q4. Non-trading days can be discounted (obviously) and that means the RNS update will arrive next week (wc12th) , the following (wc19th) or between 27th - 31st… I am seriously excited for the next update, not least because it will land at the happiest time of the year. But please, don’t start saying things are “delayed” and referring to LFTs or that “Alan” (Alastair) is at fault with timescales, because he really isn’t. Now hurry up and get ready, you’ll be late for school.
In 12 months, with the exception of a dip in March, the share price has been very steady around £1 - £1.30… as an Investor holding an AIM stock, that’s incredibly steady in reality. Probably tells you that there’s no point watching it minute by minute. When good news land, that share price will rise very sharply (“to the moon”)…Until then (and only 1 - 4 weeks to wait) the base set in the last 12 months will continue to get even more solid. I am a very happy holder and having waited this long, am happy to wait another month, if that’s what it takes. That said, I can see an RNS regarding another diagnostic acquisition in the next fortnight.
It’s impossible for indications of progress not to be given on Thursday when AS meets with investors. I know many of us will not be attending but word will get around. Ahead of a readout - if the news wasn’t very positive - you would not put yourself in front of new investors. No one would. You do this, when you are “greasing the pan” so to speak. A very positive few days ahead IMO. My gut feeling is that we will see the PK readout in the next 10 trading days , before end of month.
It’s impossible for indications of progress not to be given on Thursday when AS meets with investors. I know many of us will not be attending but word will get around. Ahead of a readout - if the news wasn’t very positive - you would not put yourself in front of new investors. No one would. You do this, when you are “greasing the pan” so to speak. A very positive few days ahead IMO. My gut feeling is that we will see the PK readout in the next 10 trading days , before end of month.
The RNS tomorrow is not going to tell us much regards operating 'costs' that as Investors we don't already know (or at least the well researched of us do!) ... However, what will be important (and what I am most excited to see) is the "Outlook" for the coming months. It will be impossible for AS not to provide insight into what he is anticipating during Q4 and all being well there remains excitement within the company with respect to the PK readout in November. I would suggest it is also likely that the Outlook will give inference regards funding options moving forward. License deal to be announced within a matter of days / few weeks IMO.
Relax guys.
Regards,
Interim Results were published 30 September 2021.
This means they will be published one day NEXT WEEK.
On 6 April, in the Prelim results AS stated:
"Success in the ongoing Phase Ia study, which will likely read-out in the middle of 2022, will not only potentially create a valuable chemotherapy asset but will also be a first validation of the pre|CISION platform, highlighting a promising pipeline of chemotherapies with the potential to significantly improve patients’ lives..
We are CONFIDENT and EXCITED about the immediate and long-term future prospects of the Group, with both potential near-term value drivers relating to AVA6000’s clinical trial progress..."
On 12 April AVCT presented a Poster reporting on AVA6000 at the most prestigious global Cancer Research event.
Then, just over 2 weeks ago (5 September) Orphan Drug status was awarded to AVA6000 which "gives 7 years if market market exclusivity in the US. " That application process takes circa 12 weeks, so the application was made in early June.
On 1 September, AS announced the Phase 1 clinical study had advanced to the fourth and final cohort.
Seriously, what is not to like ???!
Yes ,the share price is low, but so are the volumes. That tells you everything you need to know.
I am extremely confident very good news is very close now; and so should you be!